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ABSTRACT 
 
 
 
 
 Oxaliplatin is an anticancer drug that reacts with DNA, RNA, and proteins both in 
vitro and in vivo. Our research focuses on synthesizing analogs of oxaliplatin and 
understanding how bulky ligand groups affect reaction with amino acids. (R,R)-N,N’-
dimethyl-1,2-diaminocyclohexane platinum(II) oxalate or Pt(Me2dach)(ox) varies from 
oxaliplatin or Pt(dach)(ox) in that it has one methyl group attached to each platinum 
coordinated nitrogen. Nuclear Magnetic Resonance (NMR) spectroscopy has shown that 
the reactions of N-Acetylmethionine (N-AcMet) with Pt(Me2dach)(ox) and Pt(dach)(ox) 
proceed at similar rates suggesting that the methyl groups of Pt(Me2dach)(ox) have little 
effect on the initial reaction. Whereas the reaction of Pt(dach)(ox) and N-AcMet can form 
1:1 or 1:2 complexes, Pt(Me2dach)(ox) with N-AcMet can form only 1:1 products. 
Depending on the Pt:N-AcMet ratios, Pt(dach)(ox) has the potential to form either a 
[Pt(dach)(N-AcMet-S)2]
 
or [Pt(dach)(N-AcMet-S,N)] complex. The bis product is not 
found in Pt(Me2dach)(ox) reactions because the formation of a [Pt(Me2dach)(N-AcMet-
S,O)]
+ 
product hinders the coordination of a second N-AcMet. It has therefore been 
deduced that the additional methyl groups of Pt(Me2dach)(ox) limit reaction with N-
AcMet to a 1:1 molar product. 
 
Keywords: Oxaliplatin, Cancer, Platinum, Nuclear Magnetic Resonance, Proteins 
iii 
 
 
 
 
 
 
 
 
 
 
Dedicated to those trying to connect the dots. 
 
 
 
 
 
 
 
 
 
 
iv 
 
ACKNOWLEDGEMENTS 
 
 
 
 
 Completion of my Capstone Experience necessitates thanks to many people. First 
and foremost, I would like to thank my research and academic advisor Dr. Kevin 
Williams, for providing my start in scientific research and his continued support 
throughout the learning curve. Also, a warm thanks to my committee members – Dr. 
Lester Pesterfield and Dr. Michael Smith – for making this thesis possible and for their 
guidance and assistance during the process. 
 My research experience would not have been possible without the financial 
support of several agencies. I would like to thank the Honors College for awarding me an 
Honors Development Grant, Western Kentucky University for providing me with a 
Faculty-Undergraduate Student Engagement Grant, and the Student Government 
Association (SGA) for supporting my experience through an SGA Grant. The 
Department of Chemistry has also financially and academically supported me in 
conducting and presenting this research. I would also like to thank the WKU 
Biotechnology Research Experiences for Undergraduates program for allowing me to 
pursue this research. 
 Lastly, I would like to thank my family and friends for their encouragement, 
unconditional love, and support of my work throughout college. 
v 
 
VITA 
 
 
June 4, 1992……………………………………. Born – Southfield, Michigan 
 
2010……………………………………………. Clarkston High School, Clarkston,  
            Michigan 
 
2012……………………………………………. Elizabethtown Community and  
                                                                              Technical College, Elizabethtown,  
      Kentucky 
 
2012……………………………………………. Biotechnology Research Experiences for 
                       Undergraduates, Western Kentucky  
            University 
 
2013……………………………………………..Deutscher Akademischer Austausch  
            Dienst Research Internships in Science  
            and Engineering Program 
 
 
 
PUBLICATIONS 
 
 
1. Williams, K.M.; Poynter, A.D.; Hendrie, J.D.; Jackson, D.C.; Martin, V.K. 
"Comparison of N-acetylmethionine reactivity between oxaliplatin and an oxaliplatin 
derivative with chiral (S,S) amine nitrogen atoms", Inorg. Chim. Acta, 2013, 401, 64-69. 
 
 
 
FIELDS OF STUDY 
 
Major Field: Biochemistry 
 
Minor Field: Biophysics 
 
 
 
vi 
 
TABLE OF CONTENTS 
 
 
Page 
Abstract……………………………………………………………………………………ii 
Dedication………………………………………………………………………………...iii 
Acknowledgements…………………………………………………………………….....iv 
Vita………………………………………………………………………………………...v 
List of Figures……………………………………………………………………………vii 
Chapters: 
1. Introduction………………………………………………………………………..1 
2. Methodology…………………………..…………………………………………..8 
3. Results……………………………………………………………………………14 
4. Discussion………………………………………………………………………..19 
5.  Works Cited………………………………………………………………….…..22 
 
 
 
 
 
 
vii 
 
LIST OF FIGURES 
 
 
 
 
Figure            Page 
 
 
1.1 Skeletal Structures of Platinum Based Anticancer Drugs…………………...........2 
 
1.2 Visual Depiction of the Copper Transporter 1…………………….………...........5 
 
1.3 Potential Platinum-DNA complexes………………………………………….......6 
 
2.1 Synthesis of silver oxalate………………………………………………..……….8 
 
2.2 Synthesis of 1,2-diaminocyclohexane Pt(II) dichloride…………………………..9 
 
2.3 Synthesis of 1,2-diaminocyclohexane Pt(II) oxalate………………………….....10 
 
2.4 Synthesis of N,N’-dimethyl-1,2-diaminocyclohexane Pt(II) dichloride……..….11 
 
2.5 Synthesis of N,N’-dimethyl-1,2-diaminocyclohexane Pt(II) oxalate…………....12 
 
3.1 3.33 mM Pt(dach)(ox): 6.66 mM N-AcMet 
1H NMR…………………………...14 
 
3.2 3.33 mM Pt(dach)(ox): 3.33 mM N-AcMet 
1H NMR…………………………...15 
 
3.3 10 mM Pt(Me2dach)(ox): 10 mM N-AcMet 
1
H NMR.....………………………..16 
 
3.4 [Pt(Me2dach)(ox)(N-AcMet-S,O)]
+
 formation at varied temperatures..………... 17 
 
3.5 Reaction of 5 mM Pt(dach)(ox) and Pt(Me2dach)(ox) with 1 mM N-AcMet..…..18
1 
 
CHAPTER 1 
 
 
INTRODUCTION 
 
 
Cisplatin, (SP-4-2)-Diamminedichloroplatinum, cis-DDP is an anticancer drug 
that was first synthesized by Michael Peyrone in 1845. However, the chemotherapeutic 
activity of the drug wasn’t discovered until more than a century later, in 1970, when 
Barnett Rosenberg and his research team inadvertently stumbled upon it. The research 
team was studying the growth of Escherichia coli, a type of bacteria, in the presence of 
an electric current. Platinum electrodes were used to establish electric fields, due to their 
inertness, and the E. coli did not divide, but rather elongated. It was determined that this 
anomaly was caused by the reaction of the platinum electrodes with agents in the 
bacterial solution, rather than by the electric current [1].  
The drug gained popularity as studies showed that cisplatin was a 
multidimensional anti-carcinogenic agent inhibiting the metastasis of testicular, ovarian, 
lung, and stomach cancers. During clinical research, cisplatin displayed negative side 
effects including but not limited to nephrotoxicity, neurotoxicity, and low blood mineral 
levels [1-2]. This discovery prompted investigation into safer cisplatin analogs with 
similar anticancer activity. Whereas cisplatin displays chemotherapeutic activity, its 
stereoisomer transplatin does not, for reasons discussed later.
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 The second generation anticancer drug carboplatin, cis-Diammine(1,1-
cyclobutanedicarboxylato)platinum(II), was discovered in the late 1980s. Following FDA 
approval in 2003, the drug entered the market under the trade name Paraplatin. The drug 
was found effective in fighting ovarian and non-small cell lung cancers [3]. Side effects 
of using carboplatin were greatly reduced in comparison to its parent cisplatin [4].  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Skeletal Structures of Platinum Compounds. 
3 
 
 
1,2 – Diaminocyclohexane Pt(II) Dichloride     Dach Dichloride 
1,2 – Diaminocyclohexane Pt(II) Oxalate     Dach Oxalate or Oxaliplatin 
N,N’ – Dimethyl – 1,2 –Diaminocyclohexane Pt(II) Dichloride  Me2dach Dichloride 
N,N’ – Dimethyl – 1,2 –Diaminocyclohexane Pt(II) Oxalate   Me2dach Oxalate 
N-Acetylmethionine       N-AcMet 
Deoxyribonucleic Acid       DNA 
Ribonucleic Acid        RNA 
 The third generation antineoplastic drug oxaliplatin was discovered in Japan in 
1976 by Kidani [6]. It became FDA approved in 2002 taking on the trade name Eloxatin 
[7]. Eloxatin is used in combination with 5-fluorouracil and leucovorin to treat colorectal 
cancer [8].  
 These platinum based drugs are alkylating-like agents subcategorized as metallic 
salts that exhibit anticancer activity by targeting cells with expedited replication. Due to 
the influx of agents in rapidly dividing cells, chemotherapy drugs are often uptaken; 
platinum based drugs bind to DNA and bend it thereby inhibiting transcription and 
further replication. They are cell cycle non-specific meaning they affect cells at rest [9]. 
Cisplatin, carboplatin, and oxaliplatin each react by the same mechanism, and are 
administered via intravenous (IV) injection. Once in the blood these compounds circulate 
in their inert forms – chlorides on cisplatin, biscarboxylate on carboplatin, oxalate on 
oxaliplatin – with the potential to react with proteins and other agents [10]. Platinum(II) 
compounds have a high kinetic affinity for binding proteins, and these interactions may 
play critical roles in oxidative stress [11], cellular uptake [12], or resistance pathways 
[13]. There is currently no certainty as to how these cytotoxic agents enter a cell; one 
suggestion is that these drugs passively diffuse into cells or get uptaken by the human 
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copper transporter 1 (hCTR1) [14].  
 CTR1 is a transmembrane hydrophilic copper transporter. It forms as a 
homotrimer leaving a pore composed of cysteines, methionines, and histidines through 
which copper passes. Methionines 150 and 154, and histidine 139 transport Cu(I) down a 
concentration gradient via transchelation reactions [15]. Platinum based drugs may be 
uptaken using the same mechanism, and the fact that platinum based compounds are 
attracted to the nucleophilic sulfur sites of cysteine and methionine residues strengthens 
this idea[16]. The attraction of sulfur and platinum can also be explained using Hard-Soft 
Acid-Base theory, which states that hard acids prefer to interact with hard bases and soft 
acids with soft bases. Platinum, being a 5d transition metal is considered a soft acid while 
sulfur is a known as a soft base, hence the strong interaction. Whereas lack of CTR1 
expression leads to resistance of cisplatin, carboplatin, and oxaliplatin in mammalian and 
yeast cells, overexpression enhances cellular recognition of their toxic effects thereby 
increasing influx of these agents [17].
 
This demonstrates a direct link between CTR1 and 
the anticancer activity of these platinum drugs.  
 Once inside the cell, these compounds become aquated e.g., cisplatin forming 
[Pt(NH3)2(H2O)Cl]
1+
 and ultimately [Pt(NH3)2(H2O)2]
2+
. Once they become positively 
charged and incapable of crossing the hydrophobic membrane, they are trapped within 
the cell and passively diffuse into the nucleus. The two most nucleophilic regions of 
DNA base pairs are the N7-positions of guanine and adenine. It is here where platinum 
complexes forms interstrand or intrastrand cross bridges with DNA. Potential cross-links 
include 1,2-intrastrand, 1,3-intrastrand, 1,2-interstrand, and DNA-protein adducts. 
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Figure 1.2. Visual Depiction of the Copper Transporter 1 homotrimer [14]  
 
1,2-intrastrand cross-links form 90
o
 angles between two adjacent guanine or adenine 
residues and the platinum atom, which bends the DNA duplex towards the major groove. 
This exposes the minor groove of the DNA strand to which multiple classes of proteins 
can bind, such as the damage recognition proteins human upstream binding factor (UBF), 
TATA box-binding proteins (TBP), and high-mobility group box proteins (HMGB1), and 
mismatch-repair proteins [14]. HMG-domain proteins have a high affinity for platinum-
guanine, guanine adducts [18] and binding leads to inhibition of nucleotide excision 
repair, transcription, and replication, consequentially warranting apoptosis [14]. This 
leads to chemotherapeutic activity and tumor reduction.  
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Figure 1.3. Potential cross-links of platinum drugs: (a) 1,2-interstrand (b) 1,2-
intrastrand (c) 1,3-intrastrand (d) DNA-protein adduct 
 
 
 As previously described, these drugs have the ability to bind with DNA and/or 
proteins [19]. Our lab focuses on the reactions of oxaliplatin and its derivatives with 
different amino acids found within select proteins. Previous research has shown that 
platinum based chemotherapeutic drugs react with proteins located in the blood, cytosol, 
or embedded in membranes. Research is aimed at identify how much bulk can be added 
to oxaliplatin analogs before slowing down such reactions. It is speculated that bulk 
amount and anticancer activity are inversely related. The current analog we are studying, 
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(R,R)-N,N’-dimethyl-1,2-diaminocyclohexane platinum(II) oxalate or Pt(Me2dach)(ox) is 
being studied and characterized upon reaction with N-Acetylmethionine (N-AcMet). It 
differs from oxaliplatin in that it has one methyl group attached to each of the platinum 
coordinating nitrogen atoms.  
 We have found that the additional bulk of Pt(Me2dach)(ox) does slow reaction 
with N-AcMet, but minimally. Pt(dach)(ox) has the ability to coordinate to two amino 
acids in a 1:2 Pt:N-AcMet ratio, but the bulk of Pt(Me2dach)(ox) limits reaction to a 1:1 
product in the form of a S,O-chelate. This could either prevent the compound from 
entering the cell by hindering transchelation reactions within the hCTR1 or block the 
molecule from forming Pt-DNA complexes.  
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CHAPTER 2 
 
 
METHODOLOGY 
 
 
 A JEOL Eclipse 500 MHz NMR Spectrometer was used to obtain 
1
H and 
195
Pt 
NMR spectra. Deuterium Oxide (D2O) was used as a standard reference.  
 
Several syntheses were common throughout this research in order to obtain: 
Silver Oxalate 
 Silver oxalate was synthesized by mixing 350 mg oxalic acid (C2H2O4) with 1 
 g of silver nitrate (AgNO3) in 20 mL DI H2O (1.5 mM AgNO3: 1 mM C2H2O4) 
 in an amber vial. After stirring for approximately 30 minutes the milky white 
 precipitate was run through a vacuum filtration apparatus for 5-10 minutes. The 
 vial was rinsed with ethanol to get all Ag2C2O4 out and once dry, the solid was 
 collected. Yield = 798.8 mg.  
 
 
 
 
 
FIGURE 2.1. Synthesis of silver oxalate. 
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2
Potassium Tetrachloroplatinate Dach Ligand Dach Pt(II) Dichloride
2 -
2 KCl
 (aq)
(R,R)-1,2-Diaminocyclohexane Platinum(II) Dichloride 
 The synthesis of Dach Dichloride required making two separate solutions.  
 Solution 1 consisted of 64 mg dach ligand and 5 mL of methanol in a 10 mL 
 beaker. Solution 2 involved mixing 232 mg (equi-molar amount) of potassium 
 tetrachloroplatinate (K2PtCl4) and 5 mL of DI H2O in an amber vial. Solution 
 2 was added drop-wise to solution 1 while stirring. After stirring for 2-3 hours, the 
 precipitate was collected by vacuum filtration and rinsed with water, ethanol, 
 and ether. Yield = 149 mg yellow solid. 
 
 
 
 
 
FIGURE 2.2. Synthesis of Dach Dichloride 
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Dach Dichloride Oxaliplatin
H
H
H
H
2-
Silver Oxalate
2 2 AgCl
 (s)
(R,R)-1,2-Diaminocyclohexane Platinum(II) Oxalate 
 In an amber vial, equimolar amounts of Dach Dichloride and silver oxalate were 
 dissolved in 35 mL of DI H2O (100 mg Dach Dichloride and 80 mg silver oxalate 
 was standard). They sample was put on a stir plate for two days or until 
 completely mixed. Once properly mixed, the sample was filtered via syringe 
 and a 0.2 micron non-disposable filter into a 50 mL round bottom flask to remove 
 the AgCl(s) precipitate. At this point, a laser pointer was used to check for 
 undissolved suspension. If clear, the solution was dehydrated using a rotary 
 evaporator and collected. Yield = 78.1 mg.  
 
 
 
 
 
 
 
FIGURE 2.3. Synthesis of oxaliplatin. 
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(R,R)-N,N’-Dimethyl-1,2-Diaminocyclohexane Platinum(II) Dichloride   
 The synthesis of Me2dach Dichloride required making two separate  
 solutions. Solution 1 consisted of 56.8 mg Me2dach ligand and 5 mL of   
 methanol in a 10 mL beaker. Solution 2 involved mixing 166 mg (equi-  
 molar amount) of potassium tetrachloroplatinate (K2PtCl4) and 5 mL of   
 DI H2O in an amber vial. Solution 2 was added drop-wise to solution 1   
 while stirring. After stirring for 2-3 hours, the yellow solution was run   
 through a vacuum filtration apparatus and rinsed with water, ethanol,   
 and ether. Yield = 124.5 mg. 
2
Potassium Tetrachloroplatinate Me2dach Ligand Me2dach Pt(II) Dichloride
2 -
2 KCl
 (aq)
 
FIGURE 2.4. Synthesis of Me2dach Dichloride. 
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Me
2
dach Pt(II) Dichloride Me2dach Oxalate
2-
Silver Oxalate
2 2 AgCl (s)
(R,R)-N,N’-Dimethyl-1,2-Diaminocyclohexane Platinum(II) Oxalate  
 In an amber vial equimolar amounts of Me2dach Dichloride and silver oxalate 
 were dissolved in 35 mL of DI H2O (84.8 mg Me2dach Dichloride and 61.7 mg 
 silver oxalate was standard). They were then put on a stir plate for two days 
 or until completely mixed. Once properly mixed, the sample was filtered via 
 syringe using a 0.2 micron non-disposable filter into a 50 mL round bottom 
 flask to remove AgCl(s) precipitate. At this point, a laser pointer was used to check 
 for undissolved suspension. If clear, the solution was dehydrated using a rotary 
 evaporator. Yield = 75.1 mg.  
 
 
 
 
 
 
 
FIGURE 2.5. Synthesis of Me2dach Oxalate 
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 These syntheses were run and reacted with N-AcMet in the following solutions to 
observe product formations and reaction kinetics. Using the results, we have 
characterized these reactions and shown that Pt(Me2dach)(ox) is limited to the formation 
of a mono-product, whereas Pt(dach)(ox) can form two products. 
 
 
*Solution A = Dissolved 3.4 mg Me2dach Oxalate in 1.2 mL D2O.  
*Solution B = Dissolve 3.8 mg N-AcMet in 1.0 mL D2O. 
 
600 µL NMR samples were prepared for various Pt:N-AcMet ratios: 
1:1 Molar Ratio  1:2 Molar Ratio  5:1 Molar Ratio 
  300 µL Solution A    300 µL Solution A  750 µL Solution A 
 200 µL D2O    100 µL D2O     200 µL D2O 
 100 µL Solution B  200 µL Solution B   50 µL Solution B 
14 
 
CHAPTER 3 
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.1. Partial 
1
H NMR Spectra of 3.33 mM Pt(dach)(ox) and 6.66 mM N-
AcMet (1:2). The Y-axes are scaled to the tallest peak and the * indicates the S-CH3 
interaction. 
 
The signals at 2.56 and 2.58 ppm coalesce upon heating to 50
o
C and represent the sulfur-
methyl hydrogens upon Pt(dach)(N-AcMet-S2)]formation. The peak at 2.02 ppm 
indicates the Ac-CH3 resonances.
Coalescence of S-CH3 
signal upon heating 
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FIGURE 3.2. Partial 
1
H NMR spectra of 3.33 mM Pt(dach)(ox) and 3.33 mM N-
AcMet (1:1). Y-axes are scaled to the tallest peak and the * indicates the S-CH3 
signals of a S,N-chelate. 
 
The three signals at 2.30, 2.37, and 2.43 ppm indicate the sulfur-methyl hydrogens after 
formation of a [Pt(dach)((N-AcMet-S,N)] complex, while the signal at 2.02 ppm 
respresents the overlap of Ac-CH3 resonances [20]. Additionally, the sharpened bis-
product signal appears upon heating reaction, suggesting a mixture of products for an 
equimolar ratio reaction.
Formation of 
Pt(dach)(N-AcMet-S)
 
  
Stereochemical signals 
of S-CH3 interaction 
Unreacted N-AcMet 
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FIGURE 3.3. Partial 
1
H NMR spectrum of 10 mM Pt(Me2dach)(ox)and 10 mM N-
AcMet (1:1). Y-axes are scaled to the tallest peak. 
 
Three doublet of doublets appear between 5.7-5.9 ppm, which are characteristic of the N-
AcMet alpha-hydrogen upon formation of the S,O-chleate [21].  
Pair of doublet 
of doublets Doublet of 
doublets 
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FIGURE 3.4. Partial 
1
H NMR spectra of [Pt(Me2dach)(N-AcMet-S,O)]
+
 at varied 
temperatures. 
 
The resonances of [Pt(Me2dach)(N-AcMet-S,O)]
+
 broaden with increased temperature, 
suggesting several species undergoing chemical exchange based on the chirality of the 
sulfur atom in the S,O-chelate.  
18 
 
 
FIGURE 3.5. Partial 
1
H NMR spectra of 5 mM a.) Pt(dach)(ox) and b.) 
Pt(Me2dach)(ox) reacted with 1 mM of N-AcMet. Each compound’s time points are 
scaled to the same factor and * represents unreacted N-AcMet. 
 
As seen, oxaliplatin and Me2dach Oxalate react at a similar rate. Each of these react with 
a half-life of approximately one hour , while after 4 hours, N-AcMet has nearly 
completely reacted. 
 
a.)  
b.) 
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CHAPTER 4 
 
 
DISCUSSION 
 
 
 We have found that Pt(dach)(ox) has the capability to form 1:1 and 1:2 Pt: N-
AcMet products whereas our novel compound Pt(Me2dach)(ox) is limited to a 1:1 molar 
ratio due to the formation of a [Pt(Me2dach)(ox)(N-AcMet-S,O)]
+ 
complex. Figure 3.1 
shows the reaction of oxaliplatin with N-AcMet in a 1:2 molar ratio. As illustrated by the 
figure, we raised the temperature to 50
o 
C to speed up the reaction and found the 
formation of a [Pt(dach)(N-AcMet-S)2] complex. The formation of this bis-product can 
be seen by the attenuation of the unreacted N-AcMet peaks and formation of product 
peaks, as well as the signals indicated by the asterisk. The asterisks represent the peaks 
that correspond to the S-CH3 interactions of our bis-product. This was further 
characterized using 
195
Pt NMR spectroscopy, which showed a peak at -3739 parts per 
million (ppm). This chemical shift falls in the range of -3600 to -3800 – the precedent for 
a PtN2S2 coordination environment [21, 22, 23]. 
 FIGURE 3.2. shows the reaction of Pt(dach)(ox) with N-AcMet in a 1:1 molar 
ratio. We have deduced that this particular reaction forms two products – [Pt(dach)(N-
AcMet-S,N)] and [Pt(dach)(N-AcMet-S2)]. Again, we note the attenuation of the 
unreacted N-AcMet peaks around 1.95 and 2.1 ppm. After 24 hours we see the formation 
of three product peaks between 2.3-2.43 ppm and after 48 hours the same peak from 
20 
 
FIGURE 3.1. arises. As previously characterized by Barnham et al., three peaks within 
this range are indicative of the sulfur-methyl hydrogens upon formation of a S,N-chelate 
[20]. Furthermore, the 
195
Pt spectrum showed signals at -3215 and -3260, which are 
characteristic of a PtN3S coordination environment [21, 22].  
 FIGURE 3.3. is part of the 
1
H NMR spectrum for the 1:1 Pt(Me2dach)(ox):N-
AcMet reaction. There are two doublets of doublets visible around 5.7 ppm and another 
doublet of doublets at 5.8 ppm that are characteristic of the alpha-hydrogen of a S,O-
chelate [17, 23]. The series of peaks between 2.4-2.7 ppm signify the sulfur-methyl 
hydrogens from the various stereoisomeric intermediate products of the sulfur atom. 
195
Pt 
NMR signals at -2870 and -2890 ppm are within the benchmark range of -2600 to -2900 
ppm for a typical PtN2SO coordination environment. After raising the temperature, as 
seen in FIGURE 3.4., the resonances broadened suggesting multiple species undergoing 
chemical exchange, thus strengthening the conclusion drawn from the peaks at 2.4-2.7 
ppm in FIGURE 3.3.. 
 Upon characterizing the reaction of Pt(Me2dach)(ox) with N-AcMet in different 
molar ratios, we found our data to be consistent throughout. Therefore, we have deduced 
that the additional bulk or methyl groups of Pt(Me2dach)(ox) limits the reaction to a 1:1 
product in the form of [Pt(Me2dach)(N-AcMet-S,O)]
+
. This would prevent the platinum 
complex from binding with DNA or proteins, inhibiting some of its aforementioned 
functions.  
 In addition to characterizing the reactions of oxaliplatin and our anolog Me2dach 
oxalate in different molar ratios with N-AcMet, we have also kinetically studied these 
21 
 
reactions. FIGURE 3.5. shows the reactions of both Pt(Me2dach)(ox) and Pt(dach)(ox) 
with N-AcMet in 5:1 Pt:N-AcMet molar ratios over four hours. In each, we see the 
attenuation of initial peaks and the complete formation of product signals after 4 hours. 
Therefore, we have concluded that Pt(Me2dach)(ox) and Pt(dach)(ox) react at similar 
rates, despite the fact that they form different products upon reaction with N-AcMet [24]. 
 Our lab has previously studied another diamine compound pair –  
ethylenediamine platinum(II) dinitrate or Pt(en)(NO3)2 and N,N,N’,N’-
tetramethylethylenediamine platinum(II) dinitrate or Pt(Me4en)(NO3)2 . Similar to our 
present compound Pt(Me2dach)(ox), Pt(Me4en)(NO3)2 has additional methyl groups 
attached to the secondary amine atoms. Interestingly, the additional bulk of 
Pt(Me4en)(NO3)2 limits product formation to a [Pt(Me4en)(N-AcMet-S,O)]
2+
. Conversely, 
Pt(en)(NO3)2 forms both bis-prodcuts and mono-products, similar to Pt(dach)(ox). As 
noted previously, the additional methyl groups of Pt(Me2dach)(ox) did not have a 
significant effect on reaction kinetics; on the contrary the four methyl groups of 
Pt(Me4en)(NO3)2 slow reaction nearly 16-fold in comparison to Pt(en)(NO3)2 [21]. These 
comparisons do not provide a conclusive relationship between substituent bulk and 
reaction rate, but demonstrate influence on product formation.
22 
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